President and Treasurer Raj Bhutani and Corporate Secretary and Quality Control Labs Director Neelam Bhutani plead not guilty in Chicago federal court to charges of entering a criminal conspiracy and to specific charges of mail fraud, wire fraud and violations of the FD&C Act. The 15-count indictment, announced Jan. 26, supercedes a five-count indictment handed down last August ("The Pink Sheet" Aug. 30, 1993, p. 19). If convicted on all counts, Raj Bhutani faces up to 62 years imprisonment and a fine of up to $3.75 mil., Neelam Bhutani could be sentenced to 52 years and the Gurnee, Ill.-based company could be fined $7.5 mil. Allegations in the new indictment include: that Alra collected an insurance claim on contaminated batches of lactulose syrup but produced and shipped finished product anyway; that Alra collected Illinois state employee training funds but did not provide promised training to its employees; that Alra offered money to a consultant to certify falsely to FDA that he had provided training to its employees; and that the Bhutanis instructed employees to lie to the grand jury investigating the company
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth